tiprankstipranks
Health Catalyst (HCAT)
NASDAQ:HCAT
US Market
HCAT
Health Catalyst
RESEARCH TOOLSreports
Want to see HCAT full AI Analyst Report?

Health Catalyst (HCAT) Stock Forecast & Price Target

457 Followers
See the Price Targets and Ratings of:

HCAT Analyst Ratings

Hold
9Ratings
Hold
2 Buy
7 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Health
Catalyst
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HCAT Stock 12 Month Forecast

Average Price Target

$2.11
▲(59.63% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $2.11 with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 59.63% change from the last price of $1.32.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.107142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.5692307692307692,1.6884615384615385,1.8076923076923077,1.926923076923077,2.046153846153846,2.1653846153846152,2.2846153846153845,2.4038461538461537,2.523076923076923,2.6423076923076922,2.7615384615384615,2.8807692307692307,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.5005494505494505,1.5510989010989011,1.6016483516483517,1.652197802197802,1.7027472527472527,1.7532967032967033,1.8038461538461539,1.8543956043956045,1.9049450549450548,1.9554945054945057,2.006043956043956,2.0565934065934064,{"y":2.107142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.4153846153846152,1.3807692307692307,1.346153846153846,1.3115384615384615,1.2769230769230768,1.2423076923076923,1.2076923076923076,1.1730769230769231,1.1384615384615384,1.103846153846154,1.0692307692307692,1.0346153846153845,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3.00Average Price Target$2.11Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on HCAT
Richard Close
Canaccord Genuity
Canaccord Genuity
$2
Buy
51.52%
Upside
Reiterated
05/12/26
Health Catalyst: Buy Rating Reiterated on Project Nexus Progress, Margin Upside, and Unchanged $2 Price Target
Stifel Nicolaus Analyst forecast on HCAT
David Grossman
Stifel Nicolaus
Stifel Nicolaus
$2
Hold
51.52%
Upside
Reiterated
05/12/26
Health Catalyst (HCAT) Gets a Hold from Stifel Nicolaus
Piper Sandler Analyst forecast on HCAT
Jessica Tassan
Piper Sandler
Piper Sandler
$2
Hold
51.52%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Health Catalyst (NASDAQ: HCAT) and Gain Therapeutics (NASDAQ: GANX)
BTIG Analyst forecast on HCAT
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT), Liquidia Technologies (NASDAQ: LQDA) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
Stephens Analyst forecast on HCAT
Jeffrey Garro
Stephens
Stephens
$2→$1.75
Hold
32.58%
Upside
Reiterated
05/12/26
Health Catalyst price target lowered to $1.75 from $2 at StephensHealth Catalyst price target lowered to $1.75 from $2 at Stephens
William Blair Analyst forecast on HCAT
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Wells Fargo Analyst forecast on HCAT
Stan Berenshteyn
Wells Fargo
Wells Fargo
$1
Hold
-24.24%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Chugai Pharmaceutical Co (Other OTC: CHGCF), Liquidia Technologies (NASDAQ: LQDA) and Health Catalyst (NASDAQ: HCAT)
Cantor Fitzgerald Analyst forecast on HCAT
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$3
Hold
127.27%
Upside
Reiterated
05/08/26
Cantor Fitzgerald Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Evercore ISI Analyst forecast on HCAT
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$3
Hold
127.27%
Upside
Reiterated
03/30/26
Evercore ISI Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Citi Analyst forecast on HCAT
Daniel Grosslight
Citi
Citi
$3.25→$2.75
Hold
108.33%
Upside
Reiterated
01/09/26
Health Catalyst price target lowered to $2.75 from $3.25 at CitiHealth Catalyst price target lowered to $2.75 from $3.25 at Citi
J.P. Morgan Analyst forecast on HCAT
Anne Samuel
J.P. Morgan
J.P. Morgan
$9
Buy
581.82%
Upside
Reiterated
05/20/25
Health Catalyst (HCAT) Receives a Buy from J.P. Morgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on HCAT
Richard Close
Canaccord Genuity
Canaccord Genuity
$2
Buy
51.52%
Upside
Reiterated
05/12/26
Health Catalyst: Buy Rating Reiterated on Project Nexus Progress, Margin Upside, and Unchanged $2 Price Target
Stifel Nicolaus Analyst forecast on HCAT
David Grossman
Stifel Nicolaus
Stifel Nicolaus
$2
Hold
51.52%
Upside
Reiterated
05/12/26
Health Catalyst (HCAT) Gets a Hold from Stifel Nicolaus
Piper Sandler Analyst forecast on HCAT
Jessica Tassan
Piper Sandler
Piper Sandler
$2
Hold
51.52%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Health Catalyst (NASDAQ: HCAT) and Gain Therapeutics (NASDAQ: GANX)
BTIG Analyst forecast on HCAT
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT), Liquidia Technologies (NASDAQ: LQDA) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
Stephens Analyst forecast on HCAT
Jeffrey Garro
Stephens
Stephens
$2→$1.75
Hold
32.58%
Upside
Reiterated
05/12/26
Health Catalyst price target lowered to $1.75 from $2 at StephensHealth Catalyst price target lowered to $1.75 from $2 at Stephens
William Blair Analyst forecast on HCAT
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Wells Fargo Analyst forecast on HCAT
Stan Berenshteyn
Wells Fargo
Wells Fargo
$1
Hold
-24.24%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Chugai Pharmaceutical Co (Other OTC: CHGCF), Liquidia Technologies (NASDAQ: LQDA) and Health Catalyst (NASDAQ: HCAT)
Cantor Fitzgerald Analyst forecast on HCAT
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$3
Hold
127.27%
Upside
Reiterated
05/08/26
Cantor Fitzgerald Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Evercore ISI Analyst forecast on HCAT
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$3
Hold
127.27%
Upside
Reiterated
03/30/26
Evercore ISI Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Citi Analyst forecast on HCAT
Daniel Grosslight
Citi
Citi
$3.25→$2.75
Hold
108.33%
Upside
Reiterated
01/09/26
Health Catalyst price target lowered to $2.75 from $3.25 at CitiHealth Catalyst price target lowered to $2.75 from $3.25 at Citi
J.P. Morgan Analyst forecast on HCAT
Anne Samuel
J.P. Morgan
J.P. Morgan
$9
Buy
581.82%
Upside
Reiterated
05/20/25
Health Catalyst (HCAT) Receives a Buy from J.P. Morgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Health Catalyst

3 Months
xxx
Success Rate
11/27 ratings generated profit
41%
Average Return
+0.34%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 40.74% of your transactions generating a profit, with an average return of +0.34% per trade.
1 Year
Richard CloseCanaccord Genuity
Success Rate
5/27 ratings generated profit
19%
Average Return
-30.82%
Copying Richard Close's trades and holding each position for 1 Year would result in 18.52% of your transactions generating a profit, with an average return of -30.82% per trade.
2 Years
xxx
Success Rate
1/13 ratings generated profit
8%
Average Return
-48.06%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 7.69% of your transactions generating a profit, with an average return of -48.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HCAT Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
1
3
2
2
Buy
2
1
2
1
3
Hold
10
7
13
8
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
9
18
11
17
In the current month, HCAT has received 5 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. HCAT average Analyst price target in the past 3 months is 2.11.
Each month's total comprises the sum of three months' worth of ratings.

HCAT Financial Forecast

HCAT Earnings Forecast

Next quarter’s earnings estimate for HCAT is $0.03 with a range of $0.01 to $0.05. The previous quarter’s EPS was $0.02. HCAT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HCAT has Performed in-line its overall industry.
Next quarter’s earnings estimate for HCAT is $0.03 with a range of $0.01 to $0.05. The previous quarter’s EPS was $0.02. HCAT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HCAT has Performed in-line its overall industry.

HCAT Sales Forecast

Next quarter’s sales forecast for HCAT is $69.44M with a range of $68.47M to $72.80M. The previous quarter’s sales results were $70.76M. HCAT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HCAT has Performed in-line its overall industry.
Next quarter’s sales forecast for HCAT is $69.44M with a range of $68.47M to $72.80M. The previous quarter’s sales results were $70.76M. HCAT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HCAT has Performed in-line its overall industry.

HCAT Stock Forecast FAQ

What is HCAT’s average 12-month price target, according to analysts?
Based on analyst ratings, Health Catalyst’s 12-month average price target is 2.11.
    What is HCAT’s upside potential, based on the analysts’ average price target?
    Health Catalyst has 59.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HCAT a Buy, Sell or Hold?
          Health Catalyst has a consensus rating of Hold which is based on 2 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Health Catalyst’s price target?
            The average price target for Health Catalyst is 2.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $3.00 ,the lowest forecast is $1.00. The average price target represents 59.63% Increase from the current price of $1.32.
              What do analysts say about Health Catalyst?
              Health Catalyst’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of HCAT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.